



PROVIDER UPDATE

Announcing the Specialty Split Fill Program.

Starting on November 1, 2023, Highmark Health Options will implement the Specialty Split Fill Program. This program allows members a trial period to ensure they can tolerate the medication before receiving the full prescription supply. The Specialty Split Fill Program targets therapies with low tolerability and discontinuation rates, prioritizing member safety. It specifically applies to members who have not filled a 90-day supply within the last 180 days.

The Specialty Split Fill Program provides members with partial medication fills (i.e., consecutive 15-day supply) for the first three months of the therapy. When the member demonstrates tolerance to the drugs after three months, they may then receive a full month supply for all subsequent fills.

Condition	Drug Name
Oral Oncology	abiraterone (Yonsa); abiraterone (Zytiga);acalabrutinib (Calquence); Adagrasib (Krazati); alectinib hcl (Alecensa); avapritinib (Ayvakit); axitinib (Inlyta); belzutifan (Welireg); bexarotene (Targretin); bosutinib (Bosulif); brigatinib (Alunbrig); cabozantinib s-malate (Cabometyx); ceritinib (Zykadia); crizotinib (Xalkori); dacomitinib (Vizimpro); dasatinib (Sprycel); elacestrant (Orserdu); entrectinib (Rozlytrek); enzalutamide (Xtandi); erdafitinib (Balversa); erlotinib (Tarceva); everolimus (Afinitor); fedratinib hcl (Inrebic); gefitinib (Iressa); gilteritinib fumarate (Xospata); glasdegib maleate (Daurismo); imatinib (Gleevec); ivosidenib (Tibsovo); larotrectinib (Vitrakvi); lorlatinib (Lorbrena); mitotane (Lysodren); mobocertinib succinate (Exkivity); neratinib (Nerlynx); nilotinib (Tasigna); niraparib tosylate (Zejula); niraparib tosylate monohydrate and abiraterone acetate (Akeega); olaparib (Lynparza); olutasidenib (Rezlidhia); osimertinib (Tagrisso); pazopanib (Votrient); pirtobrutinib (Jaypirca); rucaparib (Rubraca); ruxolitinib (Jakafi); selpercatinib (Retevmo); sonidegib (Odomzo); sorafenib (Nexavar); sotorasib (Lumakras); talazoparib tosylate (Talzenna); tazemetostat hbr (Tazverik); vismodegib (Erivedge); vorinostat (Zolinza); zanubrutinib (Brukinsa)

*Copays are prorated based on the supply received.

For more information on the Specialty Split Fill Program, call Pharmacy Services at 1-844-325-6251, Monday–Friday, 8 a.m.–7 p.m.